You are on Trendlyne United States. Click here to go to India website or make United States as your default
  1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : BIOTECHNOLOGY
  4. SPYRE THERAPEUTICS INC.

Spyre Therapeutics Inc.

XNAS: SYRE

Download real time

18.17 0.02 (0.11%)

57.74% Fall from 52W High

986.0K XNAS Volume

XNAS 21 Mar, 2025 5:30 PM (EDT)

Watchlist

Portfolio

Share
9S
12W
4O
1T
1,094.9

Market Cap

High in industry
-5.3

PE TTM

Negative PE TTM
-0.1

PEG TTM

PEG TTM is negative
3

Price to Book

Below industry Median
0.1

Beta 1Year

Very Low volatility


Insider Trading disclosures for Spyre Therapeutics Inc.

The latest disclosure was made by Cameron Turtle in Spyre Therapeutics Inc. where a trade of 370,000 Stock Option (Right to Buy) done was reported to US exchanges on Jan. 15, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Cameron Turtle Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jan 2025 370,000 370,000 - - Stock Option (Right to Buy)
Heidy King-Jones See Remarks Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jan 2025 95,500 95,500 - - Stock Option (Right to Buy)
Scott L. Burrows Chief Financial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Jan 2025 95,500 95,500 - - Stock Option (Right to Buy)
Sheldon Sloan Chief Medical Officer 15 Jan 2025 95,500 95,500 - - Stock Option (Right to Buy)
Michael Henderson Director Other type of transaction at price $ 0.00 per share. 10 Jan 2025 105,379 105,379 (0%) 0% 0 Common Stock
Jeffrey W. Albers Director Sale of securities on an exchange or to another person at price $ 36.76 per share. 06 Nov 2024 6,700 27,360 (0%) 0% 36.8 246,313 Common Stock
Jeffrey W. Albers Director Sale of securities on an exchange or to another person at price $ 36.43 per share. 25 Oct 2024 300 34,060 (0%) 0% 36.4 10,929 Common Stock
Sheldon Sloan Chief Medical Officer 01 Oct 2024 400,000 400,000 - - Stock Option (Right to Buy)
Scott L. Burrows Chief Financial Officer Sale of securities on an exchange or to another person at price $ 28.17 per share. 03 Sep 2024 18,531 116,422 (0%) 0% 28.2 522,074 Common Stock
Jeffrey W. Albers Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 May 2024 11,323 11,323 - - Stock Option (Right to Buy)
Laurie D. Stelzer Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 May 2024 11,323 11,323 - - Stock Option (Right to Buy)
Michael Henderson Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 May 2024 11,323 11,323 - - Stock Option (Right to Buy)
Sandra Milligan Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 14 May 2024 21,980 21,980 - - Stock Option (Right to Buy)
Turtle Cameron Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 9.82 per share. 15 Feb 2024 400 746,907 (2%) 0% 9.8 3,928 Common Stock
Mark McKenna C. Director Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Feb 2024 40,000 40,000 - - Stock Option (Right to Buy)
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters